These included data from 69 melanoma patients receiving anti-PD1 or anti-PD1/CTLA4 therapy [28], 40 melanoma patients receiving anti-CTLA4 [26], and the Cancer Genome Atlas cohort that predominantly includes patients not treated with ICB therapy [31]. This evidence concerns the gene CTLA4 and melanoma.